Open AccessWhole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients
Author(s) -
James S. Cordova,
HuiKuo G. Shu,
Zhongxing Liang,
Saumya Gurbani,
Lee Cooper,
Chad A. Holder,
Jeffrey J. Olson,
Brad A. Kairdolf,
Eduard Schreibmann,
Stewart G. Neill,
Constantinos G. Hadjipanayis,
Hyunsuk Shim
Publication year - 2016
Publication title -
neuro-oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/now036
Subject(s) - ex vivo , medicine , biopsy , in vivo , pathology , magnetic resonance imaging , radiation therapy , neuronavigation , radiology , biology , microbiology and biotechnology
The standard of care for glioblastoma (GBM) is maximal safe resection followed by radiation therapy with chemotherapy. Currently, contrast-enhanced MRI is used to define primary treatment volumes for surgery and radiation therapy. However, enhancement does not identify the tumor entirely, resulting in limited local control. Proton spectroscopic MRI (sMRI), a method reporting endogenous metabolism, may better define the tumor margin. Here, we develop a whole-brain sMRI pipeline and validate sMRI metrics with quantitative measures of tumor infiltration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom